Mediridge
- Company typePrivate
- Founded2009
- HeadquartersChuo, Japan
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Mediridge does
Mediridge Inc. (メディリッジ株式会社) is a privately held Japanese contract development and manufacturing organization (CDMO) and contract research organization (CRO) founded in February 2009 by Sachiko Manabe (MD, Ph.D.), headquartered in Taito-ku, Tokyo, with a dedicated GMP plasmid manufacturing facility in Uruma City, Okinawa, and a newer gene/cell therapy site at Kashiwa-no-ha, Chiba Prefecture launched in October 2024. The company delivers one-stop services spanning research and development, consulting, contract manufacturing (CMO), and contract research (CRO) for biopharmaceuticals, gene therapies, cell therapies, and regenerative medicine products, serving pharmaceutical and biotech companies (35 corporate monoclonal antibody track projects with 100% completion), diagnostic reagent manufacturers, academic research institutes (26 academic projects), and select chemical and food company research arms.
Its service portfolio is organized in three pillars: (1) R&D services — research-grade plasmid DNA, viral vectors (lentivirus, retrovirus, AAV), monoclonal antibody production (hybridoma-based and recombinant), polyclonal antibody production, peptide synthesis, stable cell line development for CHO and HEK293, tumor-bearing animal models, and pathological specimen preparation; (2) CMO services — GMP manufacturing of cell banks, plasmids (including AOF/animal-origin-free grade), viral vectors, recombinant proteins, monoclonal antibodies, and peptides; and (3) CRO services — GLP-compliant cell bank characterization, virus clearance testing (17 model viruses via TFBS Taiwan), lot release testing, and preclinical/clinical sample assays (PK, TK, ADA, neutralization). Core proprietary technology is mediated through partnerships, principally the EirGenix EG CHO K1 sv cell line and pEG expression vector system (royalty-free licensing, ~4-month stable clone selection vs typical 10–12 months) and proprietary 5'RACE + Nanopore sequencing for ~3-week antibody gene analysis.
Mediridge generates revenue through fee-for-service contract manufacturing and testing engagements priced primarily by quote on a project basis, with limited published unit pricing available for R&D peptide synthesis, pathological specimen preparation, polyclonal antibody production, and standard plasmid production. The company operates as the exclusive Japanese agent for Taiwan-based partners TFBS Bioscience (virus safety testing and viral vector GMP) and EirGenix (GMP mAb and recombinant protein), and as the Japanese distributor for Polypeptide Group's GMP peptides (manufactured in San Diego). Revenue mechanics are therefore a mix of direct service billing from the Tokyo and Okinawa facilities, add-on consulting fees, and agent/coordination fees on Taiwan-manufactured GMP output, with demand generation driven primarily by exhibition and seminar participation at Japanese academic conferences (JSGCT, JSRM, BioJapan, JCA) rather than outbound sales motion.
Mediridge firmographics
Firmographics- Name
- Mediridge
- Legal name
- メディッジ株式会社
- Website
- https://mediridge.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Mediridge industry classification
Industry- Product category
- Biopharmaceutical CDMO and CRO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
- akta.pro secondary industries
- Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)
Keywords
Where Mediridge is headquartered
LocationHeadquarters
- HQ city
- Chuo
- HQ country
- Japan
- HQ region
- Asia
Offices2 records
Markets served
Mediridge business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Manufacturing Services (CRO/CMO): Mediridge generates revenue through fee-for-service contract manufacturing and testing engagements. Services span R&D, GMP, and GLP phases across plasmid DNA, viral vectors, monoclonal antibodies, recombinant proteins, peptides, cell banks, and safety testing. Pricing is primarily quote-based, with a limited set of standardized R&D service pricing publicly available. Revenue is project-based, not recurring.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Peptide synthesis: pricing per amino acid residue (AA) |
| Unit Pricing | Pay-as-you-go | Pathological specimen preparation (price per slide) |
| Unit Pricing | Pay-as-you-go | Tumor-bearing animal preparation and animal testing services |
| Unit Pricing | Pay-as-you-go | Monoclonal antibody production - Step pricing |
| Unit Pricing | Pay-as-you-go | Polyclonal antibody production (rabbit) |
| Unit Pricing | Pay-as-you-go | R&D plasmid manufacturing (endotoxin-free grade) |
| Unit Pricing | Pay-as-you-go | GMP polyclonal antibody production |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Mediridge product offering
Product offeringCore offering
Mediridge is a Japanese biopharmaceutical contract development, manufacturing, and research organization (CDMO/CRO) offering a one-stop service portfolio spanning R&D to GMP-grade manufacturing and GLP safety testing. Services cover plasmid DNA, viral vectors (AAV, lentivirus, retrovirus), monoclonal and polyclonal antibodies, recombinant proteins, peptides, stable cell lines, cell banks, tumor-bearing animal models, and pathological specimen preparation, with regulatory consulting support for gene/cell therapy and regenerative medicine developers.
Product overview
Mediridge is a contract research and manufacturing organization (CRO/CMO) offering a comprehensive one-stop portfolio of biopharmaceutical development services. The portfolio spans three core pillars: (1) R&D Services — covering research-grade plasmid, virus vector, monoclonal/polyclonal antibody, stable cell line, peptide synthesis, tumor-bearing animal, and pathological specimen services; (2) CMO Services — providing GMP-grade manufacturing of cell banks, plasmids (R&D through GMP, including AOF grade), virus vectors (AAV, lentivirus), recombinant proteins, monoclonal antibodies, and peptides; and (3) CRO Services — including GLP cell bank characterization, virus clearance testing, lot release testing, and preclinical/clinical sample measurement. Key strategic partnerships include TFBS (Taiwan) for virus vector GMP manufacturing and safety testing, EirGenix (Taiwan) for monoclonal antibody and recombinant protein GMP manufacturing, and PolyPeptide Group (USA) for GMP peptide synthesis. Mediridge operates domestic manufacturing facilities in Tokyo and Okinawa, Japan, and obtained a Specific Cell Processing Facility Permit from Kyushu Regional Bureau of Health and Welfare in January 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- R&D Services (R&Dサービス) Research and development stage contract services covering plasmid DNA, viral vectors (AAV, lentivirus, retrovirus), monoclonal antibody production, polyclonal antibody production, stable cell line development, peptide synthesis, tumor-bearing animal models, and pathological specimen preparation. For pharmaceutical, biotech, diagnostic, and academic researchers.
- CMO Services (CMO業務) Contract manufacturing services for biopharmaceuticals including GMP cell bank manufacturing, GMP-grade plasmid DNA, GMP viral vector (AAV, lentivirus), GMP recombinant protein, GMP monoclonal antibody, and GMP peptide manufacturing. For biopharmaceutical developers, gene/cell therapy programs, and regenerative medicine developers.
- CRO Services (CRO業務) Contract research services including GLP-compliant cell bank characterization, virus clearance testing, lot release testing, and preclinical/clinical sample measurement. For biopharmaceutical manufacturers, gene/cell therapy developers, and medical device manufacturers.
- GLP Virus Clearance Testing (GLPウイルスクリアランス試験) GLP-compliant virus clearance testing delivered via TFBS (Taiwan) partner, evaluating viral removal/inactivation capacity of biopharmaceutical manufacturing processes and medical device materials. Covers 17 model viruses including X-MuLV, PRV, HSV1, HAdV, MMV, and PPV.
- GLP Lot Release Testing (GLPロットリリース試験)
Quantifiable outcome
- High-expression stable cell lines achieve 1-5 g/L productivity in ~4 months
- +3 more outcomes
Companies that use Mediridge
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Mediridge technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mediridge partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Toshiba CorporationminorMediridge entered a business partnership agreement with Toshiba Corporation and Ricoh Bio Sciences for mRNA-LNP manufacturing support. The partnership aims to provide integrated manufacturing support services for mRNA-LNP based therapeutics, leveraging Mediridge's plasmid manufacturing capabilities.
- Ricoh Bio Sciences Co., Ltd.minorMediridge entered a business partnership agreement with Toshiba Corporation and Ricoh Bio Sciences for mRNA-LNP manufacturing support. Ricoh Bio Sciences contributes manufacturing capabilities for mRNA-LNP products, with Mediridge providing plasmid manufacturing and regulatory support.
- Teijin LimitedcoreThree-party business partnership between Teijin Limited, TFBS Bioscience Inc., and Mediridge to strengthen one-stop service for regenerative medicine CDMO. The partnership aims to secure raw material supply for regenerative medicine product development and manufacturing, with Mediridge coordinating Japanese client engagement and regulatory support.
- Teijin ReGeneNet Co., Ltd.coreStrategic CDMO alliance for regenerative medicine products combining Teijin's domestic network and regulatory capabilities with Mediridge's contract service and Taiwan partner network. Teijin operates the Kashiwa-no-ha Facility (opened February 2024) for regenerative medicine CDMO. Mediridge and Teijin co-host seminars at academic conferences (e.g., JSGCT 2025 co-sponsored evening seminar).
- Development Center for Biotechnology (DCB)coreDCB is a Taiwan government-affiliated biotechnology organization. TFBS Bioscience was spun off from DCB's biological safety testing division. Mediridge's partnership network is anchored by the DCB ecosystem (via TFBS), providing GLP-compliant virus safety testing capabilities that were previously unavailable in Japan.
- TFBS Bioscience Inc.coreMediridge serves as the exclusive Japanese agent and distribution partner for TFBS Bioscience Inc. (Taiwan), which provides virus safety testing services (GLP-compliant) and GMP viral vector manufacturing (lentivirus, AAV). TFBS was spun off from Taiwan's DCB (Development Center for Biotechnology) in October 2016. Services include cell bank characterization, virus clearance testing, lot release testing, preclinical/clinical sample measurement, and GMP virus vector production.
- EirGenix Inc.coreMediridge serves as the exclusive Japanese agent for EirGenix Inc. (Taiwan), a GMP-certified CDMO for monoclonal antibodies and recombinant proteins. EirGenix operates two manufacturing sites (Xizhi and Zhubei factories) in Taiwan, with a new facility planned in Kaohsiung by 2028. Key differentiator: their proprietary EG CHO K1 sv cell line and pEG expression vector are royalty-free for manufacturing clients.
- Polypeptide GroupcorePolypeptide Group (Denmark/US) manufactures GMP peptides for Mediridge clients. Polypeptide has over 60 years of history and 30+ approved drug APIs in GMP manufacturing. US San Diego facility handles Japan-originated orders. Manufacturing scale from 1g to 100kg. Mediridge distributes their GMP peptide products in Japan.
Scale indicators5 records
Recent moves10 records
Expansion highlights6 records
Mediridge competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Global testing and CDMO services provider with deep biopharma testing capabilities including GLP bioanalytical, virus clearance, lot release and cell bank characterization — directly overlapping with Mediridge's CRO/GLP testing pillar and offering Japan/Asia presence.
- AGC Biologics: Global CDMO with mammalian cell culture, viral vector and gene therapy manufacturing capabilities and an established Japanese commercial presence. Comparable as a much larger incumbent offering overlapping plasmid, viral vector, mAb and recombinant protein services across mammalian and microbial platforms.
- Samsung Biologics: Asian-headquartered global CDMO offering large-scale mammalian biologics manufacturing and increasingly cell and gene therapy services. Comparable in modality coverage (mAb, recombinant proteins) and in serving Asia-based biotech clients, though at significantly larger commercial scale.
- Lonza Group: One of the world's largest CDMOs offering mammalian and microbial biologics, viral vectors for cell and gene therapies, and peptides. Comparable at the service-line level (mAb, viral vector, plasmid, peptide manufacturing), though Lonza operates at vastly greater scale and global reach.
- Wuxi Biologics: Asia-based global CDMO offering end-to-end biologics development, manufacturing and testing across mAbs, recombinant proteins, viral vectors and vaccines. Directly comparable on service breadth, though at vastly larger scale and with a much broader global customer base.
- Catalent (Novo Holdings): Global CDMO with biologics, viral vector, and cell therapy manufacturing capabilities. Comparable on viral vector and biologics CDMO services and on a project-based commercial model, though Catalent operates at much larger scale across multiple modalities.
Direct peers
- CMIC Holdings: Japan's largest CRO/CDMO offering preclinical, clinical, and biomanufacturing services. Most directly comparable domestic peer given similar full-service Japanese CDMO positioning, overlapping pharma/biotech client base, and strong Japanese regulatory familiarity.
- Takara Bio: Japanese life sciences company with gene therapy, cell therapy and CDMO capabilities including viral vectors (RetroNectin, lentivirus) and recombinant protein manufacturing. Highly comparable given Japanese base, gene/cell therapy CDMO focus, and overlap with academic and pharma clients.
- Polypeptide Group: Global peptide CDMO with GMP peptide manufacturing capabilities (San Diego facility referenced in Mediridge's partnership) and 30+ approved peptide APIs. Direct peer on GMP peptide manufacturing and a current commercial partner of Mediridge's Japan distribution.
Emerging players
- VectorBuilder: Global biotech CDMO specializing in custom plasmid DNA, viral vector (AAV, lentivirus, adenovirus), mRNA and protein services with rapid turnaround. Highly comparable as a younger, technology-focused CDMO in overlapping plasmid and viral vector services, though with significantly broader geographic reach and pricing scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Mediridge compliance and trust
Trust signalCompliance2 records
Mediridge financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mediridge leadership team
Management profileNumber of profiles
Profiles1 record
Mediridge funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mediridge M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mediridge
What does Mediridge do?
Mediridge is a Japanese biopharmaceutical contract development, manufacturing, and research organization (CDMO/CRO) offering a one-stop service portfolio spanning R&D to GMP-grade manufacturing and GLP safety testing. Services cover plasmid DNA, viral vectors (AAV, lentivirus, retrovirus), monoclonal and polyclonal antibodies, recombinant proteins, peptides, stable cell lines, cell banks, tumor-bearing animal models, and pathological specimen preparation, with regulatory consulting support for gene/cell therapy and regenerative medicine developers.
Is Mediridge a public or private company?
Mediridge is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mediridge founded?
Mediridge was founded in 2009. It employs 1 to 10 people.
Where is Mediridge based?
Mediridge is headquartered in Chuo, Japan, in the Asia region.
How does Mediridge make money?
One revenue line is on record: contract Manufacturing Services (CRO/CMO).
Who are Mediridge's main competitors?
Broad incumbents on record are Eurofins Scientific, AGC Biologics, Samsung Biologics, Lonza Group, Wuxi Biologics and Catalent (Novo Holdings). Direct peers are CMIC Holdings, Takara Bio and Polypeptide Group. VectorBuilder is listed as an emerging player.
Does Mediridge have an API?
No public API is recorded for Mediridge.
What industry is Mediridge in?
Mediridge's product category is Biopharmaceutical CDMO and CRO Services. Its primary akta.pro industry code is HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO, with a secondary code of HLAAACAM, Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services. Its NAICS code is 541714 and its SIC code is 8731.